- Home
- IPA
as 08-15-2025 4:00pm EST
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 98.9M | IPO Year: | 2017 |
| Target Price: | $4.00 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.27 - $2.41 | Next Earning Date: | 09-15-2025 |
| Revenue: | $17,744,713 | Revenue Growth: | 0.01% |
| Revenue Growth (this year): | 19.47% | Revenue Growth (next year): | 32.09% |
Latest ImmunoPrecise Antibodies Ltd. News
IPA Breaking Stock News: Dive into IPA Ticker-Specific Updates for Smart Investing
Business Wire
2 months ago
ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology
Simply Wall St.
2 months ago
We're Keeping An Eye On ImmunoPrecise Antibodies' (NASDAQ:IPA) Cash Burn Rate
Business Wire
2 months ago
AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies
Business Wire
2 months ago
ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery
Business Wire
3 months ago
ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts
Business Wire
3 months ago
ImmunoPrecise Antibodies (IPA) to Present at Maxim Group’s 2025 Virtual Tech Conference
Business Wire
3 months ago
IPA’s LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed
Business Wire
4 months ago
ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods
Compare IPA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IPA ImmunoPrecise Antibodies Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.